Key points
- Sponsors apply through a New Drug Application (NDA) for most chemically synthesized drugs or a Biologics License Application (BLA) for biologics.
- The legal standard is 'substantial evidence' of effectiveness from adequate and well-controlled investigations, plus a finding that the drug is safe for its intended use.
- Under PDUFA goals, standard review targets 10 months and priority review 6 months, measured from the 60-day filing date for new molecular entities.
- The FDA ends a review with either an approval or a Complete Response Letter, which explains the deficiencies that must be addressed.
- Four expedited programs (Fast Track, Breakthrough Therapy, Accelerated Approval, and Priority Review) can shorten development or review for serious conditions.
In the United States, a new prescription drug cannot be marketed until the Food and Drug Administration (FDA) approves it. Approval is not a judgment that a drug is perfect. It is a decision that, for a specific use in a specific population, the evidence shows the drug works and its benefits outweigh its known risks.
Who reviews what
Two FDA centers review most new medicines:
- The Center for Drug Evaluation and Research (CDER) reviews most small-molecule drugs and many therapeutic biologics, such as monoclonal antibodies.
- The Center for Biologics Evaluation and Research (CBER) reviews vaccines, blood products, and cell and gene therapies.
The application
After clinical trials are complete, the sponsor submits a marketing application:
| Application | Used for | Legal basis |
|---|---|---|
| New Drug Application (NDA) | Most chemically synthesized drugs | Federal Food, Drug, and Cosmetic Act, section 505 |
| Biologics License Application (BLA) | Biologics, such as antibodies, vaccines, and gene therapies | Public Health Service Act, section 351 |
An application contains everything the FDA needs to evaluate the drug: full reports of the clinical trials, preclinical data, details of how the drug is manufactured and controlled, and the proposed prescribing information (the label).
The evidence standard
Since the 1962 Kefauver-Harris Amendments, U.S. law has required substantial evidence that a drug is effective, based on adequate and well-controlled investigations. FDA regulations (21 CFR 314.126) describe what that means in practice, including a clear statement of objectives, a valid comparison with a control, methods to minimize bias, and appropriate analysis of results.
The FDA has traditionally looked for two adequate and well-controlled trials. In some circumstances, it can accept a single trial supported by confirmatory evidence, particularly when that trial is large, persuasive, and consistent across subgroups.
Step by step through the review
1. Filing
The FDA has 60 days to decide whether an application is complete enough to review. If it is not, the agency can issue a Refuse to File letter.
2. Review
If the application is filed, a multidisciplinary team reviews it. The team includes physicians, statisticians, pharmacologists, chemists, and other specialists. Reviewers often reanalyze the sponsor's data rather than accepting the sponsor's conclusions.
3. Advisory committee (sometimes)
For some applications, the FDA asks an advisory committee of outside experts to discuss the evidence in a public meeting and vote on questions about effectiveness or safety. The FDA is not bound by the vote, although it usually follows it.
4. Inspections and labeling
The FDA may inspect the manufacturing facilities and clinical trial sites. It also negotiates the final label with the sponsor, which defines the approved use, dosing, warnings, and other information.
5. Action
Each application has a PDUFA goal date, the date by which the FDA aims to act. On or before that date, the FDA issues one of two outcomes:
- an approval letter, sometimes with requirements for postmarketing studies or a Risk Evaluation and Mitigation Strategy (REMS), or
- a Complete Response Letter (CRL), which explains the deficiencies that prevent approval. A CRL is not a permanent rejection. The sponsor can fix the problems and resubmit.
How long review takes
Review timelines are set by goals agreed under the Prescription Drug User Fee Act (PDUFA). For new molecular entities, the clock starts at the end of the 60-day filing period:
| Review type | Goal | Approximate time from submission |
|---|---|---|
| Standard review | 10 months after the filing date | About 12 months |
| Priority review | 6 months after the filing date | About 8 months |
Priority review is granted to drugs that would offer a significant improvement in the treatment, diagnosis, or prevention of a serious condition. Major amendments submitted during review can extend the goal date.
Expedited programs
The FDA has four main programs to speed the development or review of drugs for serious conditions. They are described in the agency's 2014 guidance on expedited programs.
| Program | Qualifying criteria | What it provides |
|---|---|---|
| Fast Track | Treats a serious condition and addresses an unmet medical need | More frequent FDA meetings; rolling submission of the application |
| Breakthrough Therapy | Preliminary clinical evidence of substantial improvement over available therapy | All Fast Track features plus intensive FDA guidance, starting as early as Phase 1 |
| Accelerated Approval | Serious condition; effect on a surrogate endpoint reasonably likely to predict clinical benefit | Approval based on the surrogate, with confirmatory trials required afterward |
| Priority Review | Significant improvement in safety or effectiveness for a serious condition | 6-month review goal instead of 10 months |
Accelerated approval deserves particular attention. Drugs approved this way must confirm their clinical benefit in later trials. If confirmatory trials fail, the FDA can withdraw the approval for that use. A designation such as Breakthrough Therapy signals regulatory interest. It does not guarantee approval.
After approval
Approval applies to a specific use. A sponsor that wants to market the drug for another disease must usually submit a supplemental application with new evidence. The FDA continues to monitor safety after approval, and it can require label changes, new warnings, or, rarely, removal of a drug from the market.
Where to find approval records
The FDA publishes approval information in Drugs@FDA, including approval letters, labels, and, for many drugs, the FDA's own review documents. These reviews are often the most detailed public assessment of a drug's evidence. Spectral Genomics regulatory timelines are sourced from these records.
What this means for reading regulatory news
- A PDUFA date is a target, not a guarantee. The FDA can act early or miss the date, and review extensions are common after major amendments.
- An advisory committee vote is advice. It is informative but not decisive.
- A CRL can concern manufacturing or data presentation rather than efficacy, so the reason matters.
- An expedited designation shortens the path but does not lower the evidence standard for full approval.
Sources
- U.S. Food and Drug Administration. Development & Approval Process | Drugs.Regulator
- U.S. Food and Drug Administration. Guidance: Expedited Programs for Serious Conditions: Drugs and Biologics (2014).Regulator
- U.S. Food and Drug Administration. PDUFA VII: Fiscal Years 2023–2027 commitment letter.Regulator
- 21 CFR Part 314: Applications for FDA Approval to Market a New Drug.Statute / regulation
- 21 CFR 314.126: Adequate and well-controlled studies.Statute / regulation
- U.S. Food and Drug Administration. Drugs@FDA: FDA-Approved Drugs.Registry
This article is for education. It is not medical advice and not investment advice. Figures are drawn from the sources above and describe historical averages, not the prospects of any particular drug. See our editorial standards and disclaimer.